The Middle East IVD market is projected to reach $2.15 billion by 2031, driven by the increasing prevalence of infectious diseases, the growing demand for point-of-care solutions, and heightened awareness about healthcare.

(Dubai, UAE – 21 June) — Blitz Diagnostics, a pioneering company in medtech equipment, is excited to announce its entry into the in vitro diagnostics (IVD) market with an innovative point-of-care (PoC) platform. Designed to transform healthcare by delivering quicker, more accessible diagnostic results, this solution aims to enhance patient care and facilitate faster medical decisions. Currently at the pre-scaling stage, Blitz Diagnostics is well-positioned to make a significant impact in the rapidly expanding IVD industry, which is forecasted to grow from USD 94.67 billion in 2022 to USD 157.02 billion by 2030.^[1]